Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway-Reference-Cited by-同舟云学术

Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway

Published:2006-04 Issue:4 Volume:5 Page:952-961
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Chirnomas Deborah,Taniguchi Toshiyasu,de la Vega Michelle,Vaidya Ami P.,Vasserman Maria,Hartman Anne-Renee,Kennedy Richard,Foster Rosemary,Mahoney Jennifer,Seiden Michael V.,D'Andrea Alan D.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 183 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. STIL facilitates the development and malignant progression of triple-negative breast cancer through activation of Fanconi anemia pathway via interacting with KLF16;Translational Oncology;2024-08

2. Clinical Validation of the Somatic FANCD2 Mutation (c.2022-5C>T) as a Novel Molecular Biomarker for Early Disease Progression in Chronic Myeloid Leukemia: A Case–Control Study;Hematology Reports;2024-07-08

3. Fanconi anemia complementation group D2 promotes sensitivity of endometrial cancer cells to chemotherapeutic agents by inhibiting the ferroptosis pathway;BMC Women's Health;2024-01-13

4. PLGA nanoparticle-based curcumin delivery as cancer therapeutics;Curcumin-Based Nanomedicines as Cancer Therapeutics;2024

5. Next-generation DNA sequencing identifies mutated FANCD2 Gene as a novel Biomarker for monitoring early disease progression and timely therapeutic interventions in advanced phase Chronic Myeloid Leukemia patients;2023-12-19